ACT Style Guidelines
When ever possible is it best to design pages for ACTMagazine.com using as much HTML styled text as possible. This page provides guidance on designing content for the primary (center) column. Below you will also find examples of HTML styled text as it will appear in the primary column of ACTmagazine.com.
Content for the primary column should be designed to fit a maximun column width of 620 pixels.
The color palette for ACTMagazine.com is as follows:
red color: #8E0006 RED COLOR span class="red"
red link hover color: #B8000F RED COLOR
dark gray color: #333 DARK GRAY span class="darkgray"
light gray color: #333 LIGHT GRAY span class="lightgray"
yellow color: #FFFFCC YELLOW span class="yellow"
HTML styling on ACTMagazine.com:
[P] Tri tc grupo triliono la?longe, ig tiea seksa ies. Er ism okej multa ablativa, u a? peta kvanta. Veo peti ikso ol, ien danki tamen et. Ebl oj brosi pentekosto profitanto. Be mil dato maksimume, o peta estro nen. Ree si titolo kapabl vortludo. Adjektiva dikfingro kunmeta?o ik sia, armo s'joro log in. Veka krome lanta via ac. Nk elen hoketo nominativa cis, mal samo sekso dekuma da, so devi komplika int. To pro samo e?o kernovorto, far spite kasedo ekkria ut. Super turpa emfazado jen as, hago lasta iufoje io tet. Mono onjo gardi ha sia, poa centi refleksiva ut. Ia deci usono anta?eniri cit, pri alial proto frakcistreko am. Altlernejo prirespondi unu nf, iam unuj da?rigi ig. Dum rilata dekuma ut, emfazo kazablanko beda?rinde ing id, geto minimume centimetro muo um. Mal jo apud konsonanto, sur kapabl dekuma okulvitroj if. Bisi ikso sanskrito men if, hago ologi la nea. Unt ie iama pluso. To poa estro priskribo, sed bv finnlando multiplikite, vendo kvanta postesigno tio re. Cia ju proto minca, at iam na? haltostreko demandovorto. Oj mini jesa makro hot. Piko pago ekstera?o far fo, sat giga bat'o priskribo gh, ge ebl sude.
[link style in P tag] Be mil dato maksimume o peta estro nen. Ree si titolo kapabl vortludo.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.